Market Overview

UPDATE: H.C. Wainwright & Co. Initiates Coverage on OXiGENE on Anticipated Major Catalysts

Related OXGN
OXiGENE Announces Issuance Of European Patent for OXi4503 In Acute Myeloid Leukemia And Other Myeloid Malignancies
Stocks to Watch for October 08, 2014

In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on OXiGENE (NASDAQ: OXGN) with a Buy rating and $7.50 price target.

In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of OXiGENE with a BUY recommendation and a $7.50 one-year price target. We anticipate major catalysts from leading drug candidate Zybrestat to attract investors before year-end: details of the positive median progression-free survival (mPFS) results from a Phase II ovarian cancer trial could lead to a registrational Phase II/III trial in 2015, and guidance from the EMA on a registration pathway under an Exceptional Circumstances provision in anaplastic thyroid cancer (ATC) could lead to an MAA filing in early 2016.”

OXiGENE closed on Monday at $2.98.

Latest Ratings for OXGN

Nov 2014MLV & Co.Initiates Coverage onBuy
Apr 2014HC Wainwright Initiates Coverage onBuy

View More Analyst Ratings for OXGN
View the Latest Analyst Ratings

Posted-In: George B. Zavoico H.C. Wainwright & Co.Analyst Color Initiation Analyst Ratings


Related Articles (OXGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters